DOCSLIB.ORG

Comprehensive Panel, Blood

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comprehensive Panel, Blood COMPREHENSIVE PANEL, BLOOD Blood Specimens (Order Code 70510) Alcohols Analgesics, cont. Anticonvulsants, cont. Antihistamines Acetone Norbuprenorphine Gabapentin Brompheniramine Ethanol Nortramadol Lamotrigine Cetirizine Isopropanol Oxaprozin Levetiracetam Chlorpheniramine Methanol Pentoxifylline Methsuximide Cyclizine Amphetamines Phenacetin Phenytoin Diphenhydramine Amphetamine Phenylbutazone Pregabalin Doxylamine BDB Piroxicam Primidone Fexofenadine Benzphetamine Salicylic Acid* Topiramate Guaifenesin Ephedrine Sulindac* Zonisamide Hydroxyzine MDA Tapentadol Antidepressants Loratadine MDMA Tizanidine Amitriptyline Oxymetazoline* Mescaline* Tolmetin Amoxapine Pyrilamine Methcathinone Tramadol Bupropion Tetrahydrozoline Methamphetamine Anesthetics Citalopram Triprolidine Phentermine Benzocaine Clomipramine Antipsychotics PMA Bupivacaine Desipramine 9-hydroxyrisperidone Phenylpropanolamine Etomidate Desmethylclomipramine Aripiprazole Pseudoephedrine Ketamine Dosulepin Buspirone Analgesics Lidocaine Doxepin Chlorpromazine Acetaminophen Mepivacaine Duloxetine Clozapine Baclofen Methoxetamine Fluoxetine Fluphenazine Buprenorphine Midazolam Fluvoxamine Haloperidol Carisoprodol Norketamine Imipramine Mesoridazine Cyclobenzaprine Pramoxine* 1,3-chlorophenylpiperazine (mCPP) Norclozapine Diclofenac Procaine Mianserin* Olanzapine Etodolac Rocuronium Mirtazapine Perphenazine Fenoprofen Ropivacaine Nefazodone Pimozide Hydroxychloroquine Antibiotics Norclomipramine Prochlorperazine Ibuprofen Azithromycin* Nordoxepin Quetiapine Ketoprofen Chloramphenicol* Norfluoxetine Risperidone Ketorolac Ciprofloxacin* Norsertraline Thioridazine Meclofenamic Acid* Clindamycin* Nortriptyline Trifluoperazine Meprobamate Erythromycin* Norvenlafaxine Ziprasidone Metaxalone Levofloxacin* Paroxetine *Denotes screen-only analysis. Methocarbamol Tilmicosin* Protriptyline Pricing available upon request if confirmation is available. Naloxone* Anticonvulsants Sertraline Naproxen 10-monohydroxyoxcarbazepine Trazodone Carbamazepine Trimipramine Carbamazepine-10,11-epoxide Venlafaxine Felbamate Continued on the next page. SMR011v5.0 Effective Date: 7/20/2018 317-759-4TOX | AXISFORTOX.COM | [email protected] COMPREHENSIVE PANEL, BLOOD (continued) Barbiturates Cardiovascular Fentanyl Phencyclidine Amobarbital Acebutolol Acetylfentanyl Phencyclidine (PCP) Butabarbital Alprenolol* Fentanyl Propoxyphene Butalbital Amiodarone* Gastrointestinal Norpropoxyphene Pentobarbital Amlodipine Emetine Propoxyphene Phenobarbital Atenolol Metoclopramide Sedatives/Hypnotics Secobarbital Betaxolol* Ranitidine 7-aminoflunitrazepam Bath Salts Bisoprolol Methadone Desmethylflunitrazepam Alpha-PVP Butaxamine* EDDP Flunitrazepam MDPV Chlorothiazide EMDP* (only reported if Glutethimide Mephedrone Diltiazem Methadone/EDDP present) Methaqualone Methylone Disopyramide Methadone Orphenadrine Benzodiazepines Esmolol* Miscellaneous Promethazine 2-hydroxyethylflurazepam Flecainide Metaproterenol* Ramelteon 7-aminoclonazepam Furosemide Narcotics Zaleplon Alprazolam Hydrochlorothiazide Alfentanil Zolpidem Bromazepam* Labetalol Butorphanol Zopiclone Chlordiazepoxide Metoprolol Dextromethorphan Stimulants Clonazepam Mexiletine Meperidine Atomoxetine Demoxepam Nadolol Naltrexone Benzylpiperazine (BZP)* Desalkylflurazepam Nifedipine Normeperidine Caffeine* Diazepam Oxprenolol* Pentazocine Cotinine* Estazolam Papaverine Sufentanil Methylphenidate Flumazenil* Pindolol Neurologicals Nicotine* Flurazepam Procainamide Benztropine Strychnine Hydroxytriazolam Propranolol Donepezil 1,3-trifluoromethylphenylpiperazine Lorazepam Quinidine Ropinirole (TFMPP)* Lormetazepam* Reserpine Sumatriptan Urologicals Medazepam* Sotalol Trihexyphenidyl Sildenafil Nitrazepam Timolol Opiates Tadalafil Nordiazepam Triamterene 6-MAM Vardenafil Oxazepam Verapamil Codeine *Denotes screen-only analysis Confirmation pricing available upon Phenazepam Warfarin Desomorphine request. Temazepam Cocaine Dihydrocodeine Tetrazepam* Benzoylecgonine Hydrocodone Triazolam Cocaethylene Hydromorphone Cannabinoids Cocaine Morphine THC Endocrine Nalorphine* (only reported if THC-COOH Betamethasone* Opiates present) Chlorpropamide Noscapine* (only reported if Dexamethasone* Opiates present) Oxycodone Probenecid* Oxymorphone Tolbutamide Pholcodine* SMR011v5.0 Thebaine Effective Date: 7/20/2018 317-759-4TOX | AXISFORTOX.COM | [email protected].
Load more

Recommended publications
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • Toxicology Report Division of Toxicology Daniel D
    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
    [Show full text]
  • Determination of Antidepressants in Human Plasma by Modified Cloud
    pharmaceuticals Article Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry El˙zbietaGniazdowska 1,2 , Natalia Korytowska 3 , Grzegorz Kłudka 3 and Joanna Giebułtowicz 3,* 1 Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland; [email protected] 2 Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Zwirki˙ i Wigury, 02-091 Warsaw, Poland 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland; [email protected] (N.K.); [email protected] (G.K.) * Correspondence: [email protected] Received: 5 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Cloud-point extraction (CPE) is rarely combined with liquid chromatography coupled to mass spectrometry (LC–MS) in drug determination due to the matrix effect (ME). However, we have recently shown that ME is not a limiting factor in CPE. Low extraction efficiency may be improved by salt addition, but none of the salts used in CPE are suitable for LC–MS. It is the first time that the influences of a volatile salt—ammonium acetate (AA)—on the CPE extraction efficiency and ME have been studied. Our modification of CPE included also the use of ethanol instead of acetonitrile to reduce the sample viscosity and make the method more environmentally friendly. We developed and validated CPE–LC–MS for the simultaneous determination of 21 antidepressants in plasma that can be useful for clinical and forensic toxicology. The selected parameters included Triton X-114 concentration (1.5 and 6%, w/v), concentration of AA (0, 10, 20 and 30%, w/v), and pH (3.5, 6.8 and 10.2).
    [Show full text]
  • ANTIDEPRESSANTS in PLASMA by LC/MS Code LC84010
    ANTIDEPRESSANTS IN PLASMA BY LC/MS Code LC84010 This product fulfills all the requirements of Directive 98/79/ EC on in vitro diagnostic medical devices (IVD). The declaration of conformity (CE) is available upon request. Release N° 001 Antidepressants in plasma by LC/MS January 2020 CLINICAL PHARMACOLOGY INTRODUCTION Antidepressants are a class of medications used in emotional and mood disorders, which can evolve into psychosis and other symptoms such as anhedonia, self-devaluation, indecision, lack of appetite, hyperphagia, insomnia, hypersomnia, recurring thoughts of suicide or murder and somatization of pain. These drugs are divided into various classes according to their mechanism of action: - MAOIs (monoamine oxidase inhibitors); - TCA (tricyclic antidepressants); - SSRIs (selective serotonin reuptake inhibitors); - SNRI (serotonin and norepinephrine reuptake inhibitors); - NARI (noradrenaline reuptake inhibitors); - NDRI (dopamine and noradrenaline reuptake inhibitors); - DRI (dopamine reuptake inhibitors); - SSRE (serotonergic drugs); - NASSA (specific noradrenergic and serotonergic antidepressants); - Melatonergic drugs. Given the large number of antidepressants on the market and their increasing use, there is a need for physicians to monitor their plasma concentration in order to avoid episodes of overdose. This method allows the determination of a number of antidepressant drugs and their main active metabolites: amitriptyline, nortriptyline, clomipramine, norclomipramine, desipramine, desvenlafaxine, doxepine, nordoxepine, duloxetine,
    [Show full text]
  • The Role of Tricyclic Drugs in Selective Triggering of Mitochondrially-Mediated Apoptosis in Neoplastic Glia: a Therapeutic Option in Malignant Glioma?
    Radiol Oncol 2006; 40(2): 73-85. review The role of tricyclic drugs in selective triggering of mitochondrially-mediated apoptosis in neoplastic glia: a therapeutic option in malignant glioma? Geoffrey J. Pilkington1, James Akinwunmi2 and Sabrina Amar1 1Cellular & Molecular Neuro-Oncology Group, School of Pharmacy & Biomedical Sciences, Institute of Biomedical & Biomolecular Sciences, University of Portsmouth, Portsmouth and 2Hurstwood Park Neurological Centre, Haywards Heath West Sussex, UK We have previously demonstrated that the tricyclic antidepressant, Clomipramine, exerts a concentration- dependant, tumour cell specific, pro-apoptotic effect on human glioma cells in vitro and that this effect is not mirrored in non-neoplastic human astrocytes. Moreover, the drug acts by triggering mitochondrially-media- ted apoptosis by way of complex 3 of the respiratory chain. Here, through reduced reactive oxygen species and neoplastic cell specific, altered membrane potential, cytochrome c is released, thereby activating a cas- pase pathway to apoptosis. In addition, while we and others have shown that further antidepressants, in- cluding those of the selective serotonin reuptake inhibitor (SSRI) group, also mediate cancer cell apoptosis in both glioma and lymphoma, clomipramine appears to be most effective in this context. More recently, oth- er groups have reported that clomipramine causes apoptosis, preceded by a rapid increase in p-c-Jun levels, cytochrome c release from mitochondria and increased caspase-3-like activity. In addition to clomipramine we have investigated the possible pro-apoptotic activity of a range of further tricyclic drugs. Only two such agents (amitriptyline and doxepin) showed a similar, or better, effect when compared with clomipramine. Since both orally administered clomipramine and amitriptyline are metabolised to desmethyl clomipramine (norclomipramine) and nortriptyline respectively it is necessary for testing at a tumour cell level to be car- ried out with both the parent tricyclic and the metabolic product.
    [Show full text]
  • Antidepressants
    Antidepressants BMF 83 - Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals 1 in the brain, namely serotonin and noradrenaline . Everyone experiences highs and lows, but depression is characterised by 2 persistent sadness for weeks or months . With depression there is lasting feeling of hopelessness, often accompanied by anxiety. Sufferers lose interest in things that they previously enjoyed, and experience bouts of tearfulness. Rational thinking and decision 2 making are impacted. Physical manifestations include tiredness, insomnia, loss of appetite and sex drive, aches and pains . At its worst depression can cause the sufferer to feel suicidal. Depression is usually treated with a combination of counselling and drug therapy. There is also evidence that exercise can help depression. Most people with moderate or severe depression benefit from antidepressant medication. There are a wide range of 3 antidepressants on the market, which can be broadly divided according to mechanism of action ; • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Serotonin modulator and stimulators (SMSs) • Serotonin antagonist and reuptake inhibitors (SARIs) • Norepinephrine reuptake inhibitors (NRIs or NERIs) • Tetracyclic antidepressants (TeCAs) • Tricyclic antidepressants (TCAs) • Monoamine oxidase inhibitors (MAOIs) www.chiron.no | E-mail: [email protected] | Tel.: +47 73 87 44 90 | Fax.: +47 73 73 87 44 99 | BMF 83 p.1/8 , 10_16 BMF 83 - Antidepressants BMF 83 - Antidepressants 1 Today the most common first choice of medication is a SSRI , i.e. Citalopram, Escitalopram, Fluvoxamine, Paroxetine, Sertraline, Fluoxetine. Antidepressants are not addictive, but can result in withdrawal symptoms when therapy is stopped.
    [Show full text]
  • 2016-11-BMF-83 Antidepressants
    Antidepressants BMF 83 - Antidepressants BMF 83 - Antidepressants Depression is a common psychiatric disorder impacting millions of people worldwide. It is caused by an imbalance of chemicals 1 in the brain, namely serotonin and noradrenaline . Everyone experiences highs and lows, but depression is characterised by 2 persistent sadness for weeks or months . With depression there is lasting feeling of hopelessness, often accompanied by anxiety. Sufferers lose interest in things that they previously enjoyed, and experience bouts of tearfulness. Rational thinking and decision 2 making are impacted. Physical manifestations include tiredness, insomnia, loss of appetite and sex drive, aches and pains . At its worst depression can cause the sufferer to feel suicidal. Depression is usually treated with a combination of counselling and drug therapy. There is also evidence that exercise can help depression. Most people with moderate or severe depression benefit from antidepressant medication. There are a wide range of 3 antidepressants on the market, which can be broadly divided according to mechanism of action ; • Selective serotonin reuptake inhibitors (SSRIs) • Serotonin-norepinephrine reuptake inhibitors (SNRIs) • Serotonin modulator and stimulators (SMSs) • Serotonin antagonist and reuptake inhibitors (SARIs) • Norepinephrine reuptake inhibitors (NRIs or NERIs) • Tetracyclic antidepressants (TeCAs) • Tricyclic antidepressants (TCAs) • Monoamine oxidase inhibitors (MAOIs) www.chiron.no | E-mail: [email protected] | Tel.: +47 73 87 44 90 | Fax.: +47 73 73 87 44 99 | BMF 83 p.1/8 , 10_16 BMF 83 - Antidepressants BMF 83 - Antidepressants 1 Today the most common first choice of medication is a SSRI , i.e. Citalopram, Escitalopram, Fluvoxamine, Paroxetine, Sertraline, Fluoxetine. Antidepressants are not addictive, but can result in withdrawal symptoms when therapy is stopped.
    [Show full text]
  • Antidepressant Drugs in Oral Fluid Using Liquid Chromatography –Tandem Mass Spectrometry
    Journal of Analytical Toxicology, Vol. 34, March 2010 Antidepressant Drugs in Oral Fluid Using Liquid Chromatography –Tandem Mass Spectrometry Cynthia Coulter, Margaux Taruc, James Tuyay, and Christine Moore* Immunalysis Corporation, 829 Towne Center Drive, Pomona, California 91767 Abstract graines, or sleep disorders. Antidepressant drugs may also cause impairment of cognitive and psychomotor functioning An analytical procedure for the determination of widely relevant to driving, although this impairment is reportedly prescribed drugs for the treatment of depression and anxiety less severe in second generation antidepressants such as se - disorders, including amitriptyline, cyclobenzaprine, imipramine, lective serotonin reuptake inhibitors (SSRIs) than with more dothiepin, doxepin, fluoxetine, sertraline, trimipramine, traditional tricyclic antidepressants (TCAs) such as amitripty - protriptyline, chlorpromazine, clomipramine, and some of their line (1,2). Patients receiving long-term treatment with SSRI metabolites (nortriptyline, desmethyldoxepin, desipramine, and serotonin-norepinephrine reuptake inhibitor (SNRI)-type desmethyltrimipramine, norclomipramine) in oral fluid has been drugs produce impaired driving performance (3). However, developed and validated using liquid chromatography with tandem Brunnauer et al. (2) showed that there were actually no sta - mass spectral detection. The oral fluid samples were collected using the Quantisal™ device, screened with enzyme-linked tistically significant differences between patients treated
    [Show full text]
  • Validation of Cotinine As a Selective Probe Substrate, Inhibition by UGT Enzyme-Se
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2015/12/15/dmd.115.068213.DC1 1521-009X/44/3/378–388$25.00 http://dx.doi.org/10.1124/dmd.115.068213 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 44:378–388, March 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition s Attarat Pattanawongsa, Pramod C. Nair, Andrew Rowland, and John O. Miners Department of Clinical Pharmacology (A.P., P.C.N., A.R., J.O.M.) and Flinders Centre for Innovation in Cancer (A.R., P.C.N., J.O.M.), Flinders University School of Medicine, Adelaide, Australia Received November 2, 2015; accepted December 14, 2015 ABSTRACT Downloaded from Although there is evidence for an important role of UGT2B10 in the antidepressant and antipsychotic drugs screened for effects on N-glucuronidation of drugs and other xenobiotics, the inhibitor UGT2B10 inhibited enzyme activity with IC50 values <100 mM. The selectivity of this enzyme is poorly understood. This study sought most potent inhibition was observed with the tricyclic antidepres- primarily to characterize the inhibition selectivity of UGT2B10 by sants amitriptyline and doxepin and the tetracyclic antidepressant UDP-glucuronosyltransferase (UGT) enzyme-selective inhibitors mianserin, and the structurally related compounds desloratadine dmd.aspetjournals.org used for reaction phenotyping, and 34 antidepressant and antipsy- and loratadine. Molecular modeling using a ligand-based approach chotic drugs that contain an amine functional group.
    [Show full text]
  • Attachment F
    Attachment F Miami-Dade Medical Examiner Fee Schedule The Miami-Dade County Medical Examiner Department will impose the charges listed below for each of the services identified: Expert Witness Fees Fees for expert testimony services provided by the medical, toxicology, and other professional staff are comparable to those charged in the private sector. Hourly rates are billable to the nearest quarter of an hour. District Medical Examiner, Associate Medical Examiner, and Toxicology Laboratory Director Court time, deposition time, conference and phone conference time $330/hr or $2,200/day Review of records and Preparation time $110/hr Wait or travel time to testify in court or at deposition (up to one-hour, thereafter at “Court time . .” rate) $85/hr Other Professional Staff (including Toxicologist, Investigators, Photographers, and Supervisors Court time, deposition time, conference and phone conference time $165/hr or $1,100/day Review of records and Preparation time $85/hr Wait or travel time to testify in court or at deposition (up to one-hour limit thereafter at “Court time . .” rate) $55/hr Medical Examiner Approval Fees Florida statutes mandate that the Medical Examiner review each body disposition request arising within the county that involves cremation, anatomical donation, burial at sea, or fetal death. $65/case Indigent Cremation Services The Indigent Cremation Services(ICS) program assists indigent families with final disposition. Families providing proof of receiving current government assistance under one or more of the programs listed below will pay: $110 • Food Stamps • Medicaid • Supplemental Security Income • Temporary Assistance for Needy Families Families unable to provide proof of receiving current government assistance will be charged a fee equivalent to the per-cremation cost incurred by Miami-Dade County of: $400 2 * All hourly rates are billable to the nearest quarter of an hour.
    [Show full text]
  • Antidepressants
    Pharmacokinetics of Antidepressants Jose de Leon, MD (11-01-15) Learning Objectives After completing this presentation, the participant should be able to: 1) Appreciate the relevance of absorption, renal and hepatic impairment for some antidepressants. 3) Summarize major metabolic pathways of: (a) tricyclic antidepressants, (b) selective serotonin reuptake inhibitors, (c) selective noradrenergic reuptake inhibitors, and (d) others. 4) Be aware that antidepressants can be involved in clinically-relevant drug-drug interactions since: (a) some antidepressants are inhibitors, and (b) inducers, inhibitors and pregnancy can influence their metabolism. Warning This is an extraordinarily long presentation: 1) You may need to read it more than once until you have become familiar with key aspects. More importantly, you need to practice every day and review the pharma- cokinetics of drugs when any of your patients are taking antidepressants in the context of polypharmacy. 3) The most important concept to remember is that some antidepressants are clinically significant inhibitors of the metabolism of some other drugs. See the “Do Not Forget” Section. See important facts in red. 4) The section on CYP genotyping is very complex if you are not familiar with these concepts. If you want to understand it better, please review the lecture titled, “Pharmacogenetic Testing in Psychiatry”. Abbreviations ■ ADR: adverse drug reaction ■ AED: antiepileptic drug ■ C: concentration ■ C/D ratio: concentration-to-dose ratio ■ CYP: cytochrome P450 ■ CYP2C: CYP2C8, CYP2C9 & CYP2C19 ■ D: dose ■ DDI: drug-drug interaction ■ GFR: glomerular filtration rate ■ nor=desmethyl when describing metabolites. norclomipramine=desmethylclomipramine ■ TDM: therapeutic drug monitoring ■ UGT: uridine diphosphate glucuronosyltransferase Abbreviations of Included Antidepressants This presentation focuses on: ■ TCAs: tricyclic antidepressants Only 5 TCAs are described.
    [Show full text]
  • Bindex 877..922
    j877 Index a acetone Abrus precatorius L. (jequirity bean) 804 – BAT value 520, 853 absinth 516 – blood concentration 520 absorption spectrophotometry (AS) 652–656, – clinical interpretation 522 668–671 – headspace-GC 171, 173, 519 ACE (angiotensin converting enzyme) – medical assessment 520 inhibitors – toxicity 522 – GC-MS 161 acetonitrile acebutolol – headspace-GC 171, 173 – HPLC 457 – hepatotoxicity 749 acenocoumarol 303 – protein precipitation 119 – HPLC 305 acetorphine 867 acephate acetylcholinesterase (AChE) – ADI value 596 – BAT value 853 – MAK value 596 – determination 760 – TLC 594 – enzyme stability 763 aceprometazine – half-life of inhibited AChE 762 – TBPE test 179 – metabolite binding 702 acetaldehyde (ethanal) acetylcholinesterase (AChE) inhibitor – headspace-GC 171, 173 – BAT value 853 acetamidoflunitrazepam acetyldigoxin 336 – HPLC 355 – elimination half-life 841 acetaminophen, see also paracetamol – plasma/serum concentration 841 – antidote 857 acetylmethadol 867 – clinical interpretation 205 6-acetylmorphine – elimination half-life 204, 841 – elimination half-life 247 – extraction 190 – GC–MS 247 – GC 198 – pharmacokinetics 247 – GC–MS 109, 112, 116 N-acetylprocainamide – HPLC 109, 112, 116, 193 – clinical interpretation 281 – immunoassay 203 – elimination half-life 281 – intoxication 144 – immunoassay 781 – medical assessment 204 – medical assessment 281 – metabolism 206 – metabolism 281 – plasma/serum concentration 841 – serum concentration 281 – serum concentration 204 acetylsalicylic acid 209 – toxic hemorrhagic
    [Show full text]